Medication overuse headache in migraine
This is a Phase IV study, evaluating the efficacy of the approved migraine drug eptinezumab, combined with a brief behavioural intervention, for prevention of migraine and treatment of medication overuse headache in patients with a dual diagnosis of migraine and medication overuse headache. At the start of the study, participants will be instructed to stop taking acute headache medications during a semi-structured educational conversation. Participants will then be randomly assigned to receive eptinezumab or placebo by intravenous infusion for a 12 week period. After that, all participants will receive eptinezumab for another 12 weeks. Efficacy of the study intervention will be measured using headache diaries and health questionnaires completed on a mobile electronic device.